<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585803</url>
  </required_header>
  <id_info>
    <org_study_id>KMRC011-01</org_study_id>
    <nct_id>NCT03585803</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011</brief_title>
  <official_title>A Dose Blocked-Randomized, Single-Blind, Placebo-Controlled and Dose-Escalation Phase I Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011 After Intramuscular Administration in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intron Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intron Biotechnology, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to evaluate the safety, tolerability, pharmacokinetic and
      pharmacodynamic of KMRC011 injection in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with treatment-emergent adverse event or adverse drug reaction</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant changes in hematology test result after injection</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant changes in blood chemistry test result after injection</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant changes in urinalysis test result after injection</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant changes in blood coagulation test result after injection</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant changes in ECG (Electrocardiogram) after injection</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant changes in vital sign after injection</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant physical abnormality after injection</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum concentration (Cmax) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of the maximum serum concentration (Tmax) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration versus time curve, from time 0 to the last measurable concentration (AUC0-t) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration versus time curve from time 0 to infinity (AUCinf) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of AUCinf due to extrapolation from time of last measurable concentration to infinity (AUCextra) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance (CL/F) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vd/F) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t1/2) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum effect over the time span specified (Emax) of G-CSF</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum effect over the time span specified (Emax) of IL-6</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the effect versus time curve, from time 0 to the last measurable concentration (AUEC0-t) of G-CSF</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the effect versus time curve, from time 0 to the last measurable concentration (AUEC0-t) of IL-6</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of KMRC011</measure>
    <time_frame>Until the study completion, approximately up to 35 weeks</time_frame>
    <description>A dose that is one level lower than the dose which Dose Limiting Toxicity (DLT) incidence is 33% or more is determined as a Maximum Tolerated Dose (MTD). If the Dose Limiting Toxicity (DLT) incidence is lower than 33% at all doses level, we conclude Maximum Tolerated Dose (MTD) cannot be determined.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of subjects who expressed Anti-Drug (KMRC011) Antibody (ADA)</measure>
    <time_frame>Up to 28±2 days after injection</time_frame>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Acute Radiation Syndrome</condition>
  <arm_group>
    <arm_group_label>KMRC011 5μg or Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KMRC011 10μg or Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KMRC011 20μg or Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KMRC011 30μg or Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KMRC011 45μg or Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KMRC011 60μg or Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KMRC011 75μg or Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KMRC011 5μg or Placebo</intervention_name>
    <description>Intramuscular Injection of KMRC011 5μg or Placebo(Normal Saline) 0.1ml</description>
    <arm_group_label>KMRC011 5μg or Placebo</arm_group_label>
    <other_name>Cohort 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KMRC011 10μg or Placebo</intervention_name>
    <description>Intramuscular Injection of KMRC011 10μg or Placebo(Normal Saline) 0.2ml</description>
    <arm_group_label>KMRC011 10μg or Placebo</arm_group_label>
    <other_name>Cohort 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KMRC011 20μg or Placebo</intervention_name>
    <description>Intramuscular Injection of KMRC011 20μg or Placebo(Normal Saline) 0.4ml</description>
    <arm_group_label>KMRC011 20μg or Placebo</arm_group_label>
    <other_name>Cohort 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KMRC011 30μg or Placebo</intervention_name>
    <description>Intramuscular Injection of KMRC011 30μg or Placebo(Normal Saline) 0.6ml</description>
    <arm_group_label>KMRC011 30μg or Placebo</arm_group_label>
    <other_name>Cohort 4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KMRC011 45μg or Placebo</intervention_name>
    <description>Intramuscular Injection of KMRC011 45μg or Placebo(Normal Saline) 0.9ml</description>
    <arm_group_label>KMRC011 45μg or Placebo</arm_group_label>
    <other_name>Cohort 5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KMRC011 60μg or Placebo</intervention_name>
    <description>Intramuscular Injection of KMRC011 60μg or Placebo(Normal Saline) 1.2ml</description>
    <arm_group_label>KMRC011 60μg or Placebo</arm_group_label>
    <other_name>Cohort 6</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KMRC011 75μg or Placebo</intervention_name>
    <description>Intramuscular Injection of KMRC011 75μg or Placebo(Normal Saline) 1.5ml</description>
    <arm_group_label>KMRC011 75μg or Placebo</arm_group_label>
    <other_name>Cohort 7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male whose age is between 19 and 55 years of age

          -  A person whose body mass index is between 18.5 and 27 kg/m2 at screening

          -  A person who has the ability and willingness to participate in the clinical trial

          -  A person who voluntarily agrees with the clinical trial after hearing and fully
             understanding the detailed explanation of this clinical trial

        Exclusion Criteria:

          -  A person who has a clinically significant disease or history of liver, kidney,
             neuropsychiatry, immune system, respiratory system, endocrine system,
             hematology*oncology system, cardiovascular system, etc.(In the case of liver disease
             items, it includes subjects who have hepatitis virus)

          -  A person who has clinical history of hypersensitivity reactions to the major
             components or constituents of investigational product or other clinically significant
             hypersensitivity reactions to drugs or foods, or those with allergic diseases
             requiring treatment

          -  A person with infectious disease or severe trauma within 21 days of the randomization
             date

          -  A person whose serum AST, ALT or γ-GT levels exceed 1.5 times the upper limit of the
             reference range at screening

          -  A person whose QTcF on the electrocardiogram exceeds 430 msec or who has a clinically
             significant abnormal rhythm at screening

          -  A person with a glomerular filtration rate less than 60 mL/min/1.73 m2 calculated from
             serum creatinine at screening

          -  A person with a systolic blood pressure less than 100 mmHg, greater than 150 mmHg,
             diastolic blood pressure less than 60 mmHg, or greater than 100 mmHg at screening

          -  A person with thrombocytopenia or coagulopathy which should not be given intramuscular
             injection

          -  A person whose weekly average drinking amount exceeds 140g of alcohol per week

          -  A person whose daily average smoking amount exceeds 10 per day

          -  A person who have received a drug that can significantly affect the absorption,
             distribution, metabolism or excretion of the investigational product within 14 days of
             the injection

          -  A person who has the history of substance abuse or positive urine screening test

          -  A person who have received a investigational product or a bioequivalence study drug
             within at least 90 days prior to the randomization

          -  A person who donated whole blood within 60 days before the randomization, or donated
             components of blood within 30 days

          -  A person who dose not have a medically approved contraceptive during the trial and has
             a plan to provide sperm

          -  A person who has clinically significant abnormalities from clinical laboratory test

          -  A person who is deemed ineligible for clinical trials by the investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-Ryul Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sooyoun Jun, PhD</last_name>
    <phone>+82-31-739-5332</phone>
    <email>jsy@intron.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Gangnam-gu</city>
        <state>Seoul</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung-Ryul Kim, MD, PhD</last_name>
      <phone>+82-2-3410-3686</phone>
      <email>jungryul.kim@samsung.com</email>
    </contact>
    <contact_backup>
      <last_name>Seokuee Kim, MD, PhD</last_name>
      <phone>+82-2-3410-0636</phone>
      <email>seokuee.kim@samsung.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>July 2, 2018</last_update_submitted>
  <last_update_submitted_qc>July 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiation Injuries</mesh_term>
    <mesh_term>Acute Radiation Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

